Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to $27000.0.

  • Dianthus Therapeutics' Depreciation and Depletion rose 800.0% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $110000.0, marking a year-over-year increase of 2222.22%. This contributed to the annual value of $96000.0 for FY2024, which is 4328.36% up from last year.
  • Dianthus Therapeutics' Depreciation and Depletion amounted to $27000.0 in Q3 2025, which was up 800.0% from $30000.0 recorded in Q2 2025.
  • Dianthus Therapeutics' Depreciation and Depletion's 5-year high stood at $30000.0 during Q2 2025, with a 5-year trough of $6000.0 in Q3 2022.
  • In the last 4 years, Dianthus Therapeutics' Depreciation and Depletion had a median value of $22000.0 in 2024 and averaged $20384.6.
  • In the last 5 years, Dianthus Therapeutics' Depreciation and Depletion soared by 21666.67% in 2023 and then skyrocketed by 800.0% in 2025.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Depreciation and Depletion stood at $11000.0 in 2022, then soared by 81.82% to $20000.0 in 2023, then rose by 30.0% to $26000.0 in 2024, then rose by 3.85% to $27000.0 in 2025.
  • Its last three reported values are $27000.0 in Q3 2025, $30000.0 for Q2 2025, and $27000.0 during Q1 2025.